ReviewFrontiers in pharmacology2026
ALIAmides and pediatric health: a structured narrative review.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although most children require medications only for occasional acute conditions, a significant proportion lives with chronic diseases that necessitate long-term, often multiple treatments, which negatively impact their health and quality of life, and may lead to adverse outcomes. Challenges related to prescribing and formulation further complicate pediatric treatment, underscoring the need for safe and effective innovative strategies. Autacoid Local Injury Antagonism amides (ALIAmides), particularly palmitoylethanolamide (PEA) and Adelmidrol, represent promising therapeutic options. This structured narrative review aims to collect and discuss all available literature on PEA and Adelmidrol use in pediatric patients. Methods: A search of PubMed, Scopus, and the Cochrane Library identified 17 studies involving a total of 2,530 patients, of whom 1,772 received PEA (oral or topical), and 54 received Adelmidrol. Following a transdiagnostic approach, results were organized by symptom domains rather than by specific diagnoses, to capture potential benefits across multiple conditions and facilitate comparison with previous studies. Data extraction included study design, population characteristics, intervention type and formulation, outcomes assessed, and main findings. Results: Beneficial effects on behavioral, cognitive, motor, and visceral functions, along with improvements in respiratory and dermatological disorders emerged from studies administering oral PEA, mostly in micron-sized formulations. Topical application of both PEA and Adelmidrol also demonstrated benefits on respiratory and skin conditions. Conclusion: Overall, the findings of this review suggest that PEA and Adelmidrol may represent promising, well-tolerated adjunctive strategies for managing pediatric symptoms across various clinical conditions, particularly those that are chronic or require polypharmacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.